OPRX

Healthcare

OptimizeRx Corp. · Medical - Healthcare Information Services · $120M

UQS Score — Balanced Preset
58.7
Good

OptimizeRx Corp. scores 58.7/100 using the Balanced preset.

UQS vs Healthcare Sector
OPRX
58.7
Sector avg
32.4
Quality
Neutral
Moat
Weak
Growth
Good
Risk
Good
Valuation
Attractive

Unlock Full OPRX Analysis

Sign in to unlock the detailed analysis behind the UQS Score.

  • ✓Detailed 6-pillar UQS breakdown with exact scores
  • ✓All 29 metrics with sector-calibrated comparisons
  • ✓6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
  • ✓Watchlist tracking with score alerts
  • ✓AI-generated investment perspectives across 6 preset views
  • ✓Score history chart with change notifications
Analyze OPRX in Detail →

Pro Analysis

OPRX — Score History

50556065Jul 11Jul 29Aug 16Sep 3Sep 21Oct 8
Score changes· 8 most recent
DateUQSQualityMoatGrowthRiskValueChange
Jul 29, 202659.053.829.060.875.898.3+0.1
Jul 24, 202658.953.829.060.875.897.9+0.1
Jul 22, 202658.853.829.060.875.897.4-0.1
Jul 16, 202658.953.829.060.875.897.80.0
Jul 15, 202658.953.829.060.875.898.10.0
Jul 14, 202658.953.829.060.875.897.7-0.1
Jul 12, 202659.053.829.060.875.898.30.0
Jul 11, 202659.053.829.060.875.898.4—

OPRX — Pillar Breakdown

◆

Quality

— 53.8/100 (25%)

OptimizeRx Corp. has average quality metrics, with room for improvement in margins or capital efficiency.

Capital Efficiency (ROIC)Weak

How effectively capital is deployed to generate returns.

Return on EquityWeak

Profitability relative to shareholders' equity.

Operating ProfitabilityModerate

Ability to convert revenue into operating profit.

Net ProfitabilityWeak

Bottom-line profit as a share of revenue.

Gross Profit / AssetsStrong

Asset productivity — how much gross profit each dollar of assets generates.

Cash GenerationStrong

Free cash flow relative to market value.

▲

Growth

— 60.8/100 (20%)

OptimizeRx Corp. demonstrates healthy growth trends across revenue and earnings.

Recent Revenue TrendModerate

Revenue trajectory over the last twelve months.

3Y Revenue CAGRModerate

Compound annual revenue growth rate over 3 years.

EPS GrowthStrong

Year-over-year earnings per share growth.

Forward Revenue OutlookWeak

Analyst consensus for future revenue growth.

Forward EPS GrowthStrong

Analyst consensus for future earnings growth.

◈

Risk

— 75.8/100 (15%)

OptimizeRx Corp. carries minimal financial risk with conservative leverage and strong solvency.

Financial LeverageStrong

Debt levels relative to earnings capacity.

Debt/EquityStrong

Total debt relative to shareholder equity.

Current RatioStrong

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageWeak

Earnings capacity relative to interest payments.

●

Valuation

— 96.8/100 (15%)

OptimizeRx Corp. appears attractively valued relative to its earnings, cash flows, and sector peers.

Earnings YieldStrong

Inverse of forward P/E — higher yield means cheaper stock.

Price to Free Cash FlowStrong

How many years of FCF the market cap represents.

PEG RatioStrong

P/E relative to earnings growth — lower is more attractive.

EV/EBITDA vs SectorStrong

Enterprise value multiple relative to sector median.

⬡

Moat

— 29/100 (25%)

OptimizeRx Corp. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OPRX.

Score Composition

Quality
53.8×25%13.4
Growth
60.8×20%12.2
Risk
75.8×15%11.4
Valuation
96.8×15%14.5
Moat
29.0×25%7.3
Total
58.7Good

Financial Data

More Stock Analysis

How is the OPRX UQS Score Calculated?

The UQS (Unified Quality Score) for OptimizeRx Corp. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses OptimizeRx Corp.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether OptimizeRx Corp. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.